secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001140361-25-032502
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma CFO resigns; General Counsel named interim CFO
------------------------------------------------------------

- Aaron Ondrey resigned as CFO effective September 5, 2025 to pursue other opportunities.
- Martin Wilson, General Counsel and Chief Corporate Officer, appointed interim Principal Financial Officer effective September 8, 2025.
- Wilson joined Rocket in November 2021; has nearly 20 years of life sciences legal and executive experience.
- No family relationships or transactions with the company beyond compensation for current roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/0001140361-25-032502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/ef20054457_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer